323 related articles for article (PubMed ID: 33097661)
1. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Wei X; Yang J; Adair SJ; Ozturk H; Kuscu C; Lee KY; Kane WJ; O'Hara PE; Liu D; Demirlenk YM; Habieb AH; Yilmaz E; Dutta A; Bauer TW; Adli M
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28068-28079. PubMed ID: 33097661
[TBL] [Abstract][Full Text] [Related]
2. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR
Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886
[TBL] [Abstract][Full Text] [Related]
3. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
4. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
Dunlop CR; Wallez Y; Johnson TI; Bernaldo de Quirós Fernández S; Durant ST; Cadogan EB; Lau A; Richards FM; Jodrell DI
Br J Cancer; 2020 Oct; 123(9):1424-1436. PubMed ID: 32741974
[TBL] [Abstract][Full Text] [Related]
5. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
6. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
7. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
8. Precise and efficient silencing of mutant Kras
Jiang W; Li H; Liu X; Zhang J; Zhang W; Li T; Liu L; Yu X
Theranostics; 2020; 10(25):11507-11519. PubMed ID: 33052229
[No Abstract] [Full Text] [Related]
9. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
[TBL] [Abstract][Full Text] [Related]
11. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.
Ferro R; Adamska A; Lattanzio R; Mavrommati I; Edling CE; Arifin SA; Fyffe CA; Sala G; Sacchetto L; Chiorino G; De Laurenzi V; Piantelli M; Sansom OJ; Maffucci T; Falasca M
Oncogene; 2018 Dec; 37(49):6368-6382. PubMed ID: 30061636
[TBL] [Abstract][Full Text] [Related]
12. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.
Wu L; Ge Y; Yuan Y; Li H; Sun H; Xu C; Wang Y; Zhao T; Wang X; Liu J; Gao S; Chang A; Hao J; Huang C
Cancer Lett; 2022 Nov; 548():215864. PubMed ID: 35981571
[TBL] [Abstract][Full Text] [Related]
14. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
15. Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
Prabhu L; Wei H; Chen L; Demir Ö; Sandusky G; Sun E; Wang J; Mo J; Zeng L; Fishel M; Safa A; Amaro R; Korc M; Zhang ZY; Lu T
Oncotarget; 2017 Jun; 8(25):39963-39977. PubMed ID: 28591716
[TBL] [Abstract][Full Text] [Related]
16. The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.
Xie F; Huang M; Lin X; Liu C; Liu Z; Meng F; Wang C; Huang Q
Sci Rep; 2018 May; 8(1):8102. PubMed ID: 29802402
[TBL] [Abstract][Full Text] [Related]
17. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
18. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
19. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]